[Federal Register Volume 67, Number 26 (Thursday, February 7, 2002)]
[Notices]
[Page 5831]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-2950]



[[Page 5831]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory 
Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Pediatric Oncology Subcommittee of the Oncologic 
Drugs Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA regulatory issues.
    Date and Time: The meeting will be held on March 12, 2002, from 8 
a.m. to 5 p.m.
    Location: CDER Advisory Committee Conference Room, Rm. 1066, 5630 
Fishers Lane, Rockville, MD.
    Contact Person: Thomas H. Perez or Kimberly Littleton Topper, 
Center for Drug Evaluation and Research (HFD-21), Food and Drug 
Administration, 5600 Fishers Lane, Rockville, MD 20857, by phone at 
301-827-7001, or by e-mail at [email protected] or 
[email protected], or FDA Advisory Committee Information Line, 1-
800-741-8138 (301-443-0572 in the Washington, DC area), code 12542. 
Please call the Information Line for up-to-date information on this 
meeting.
    Agenda: The subcommittee will discuss potential conflicts of 
interest in pediatric oncology clinical trials, off-protocol patient 
access to investigational drugs, and access to investigational drugs 
for nonclinical studies.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the subcommittee. 
Written submissions may be made to the contact person by March 4, 2002. 
Oral presentations from the public will be scheduled between 
approximately 8:15 a.m. and 12:45 p.m. Time allotted for each 
presentation may be limited. Those desiring to make formal oral 
presentations should notify the contact person before March 4, 2002, 
and submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Thomas H. Perez or 
Kimberly Littleton Topper at least 7 days in advance of the meeting.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: January 31, 2002.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 02-2950 Filed 2-6-02; 8:45 am]
BILLING CODE 4160-01-S